Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TRKing down drug resistance in NTRK fusion-positive cancers†.

The Journal of pathology - 1 Oct 2024

Parrish Abigail G, Szulzewsky Frank

Abstract excerpt

In a recent issue of The Journal of Pathology, Chen and colleagues established novel patient-derived ex vivo models of NTRK fusion-positive soft tissue sarcoma to characterize resistance mechanisms against targeted therapy with tyrosine kinase inhibitors. Prolonged exposure to escalating concentrations of the tyrosine kinase inhibitor, entrectinib, ultimately led to the occurrence of resistant clones that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neurofibromin 2

Share to Oncogene Proteins, Fusion

Share to Receptor, trkA

Share to Sarcoma

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 39072755
DOI: 10.1002/path.6341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TRKing down drug resistance in NTRK fusion-positive cancers†.PMID 39072755Read ↗

Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.Semantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

How I treat NTRK gene fusion-positive cancersSemantic proximity Read ↗

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Semantic proximity Read ↗

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasSemantic proximity Read ↗

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

Novel fusion sarcomas including targetable NTRK and ALK.Semantic proximity Read ↗

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor ResistanceSemantic proximity Read ↗

Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Semantic proximity Read ↗

NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic ReviewSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

The First Case Treated with Larotrectinib of a Novel TMTC2-NTRK3 Fusion Undifferentiated High-Grade Pleomorphic Sarcoma of the ChestSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.